Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing deal

Roche Holding AG made its second major gene therapy deal in a year on Monday, spending $1.15 billion to obtain the rights to Sarepta Therapeutics Inc's investigational drug to treat duchenne muscular dystrophy (DMD) outside the United States.

from Reuters: Health News https://ift.tt/2rn51un